Organogenesis Holdings Inc (NASDAQ:ORGO) price on Thursday, May 01, rose 1.02% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $4.96.
A look at the stock’s price movement, the close in the last trading session was $4.91, moving within a range at $4.76 and $4.97. The beta value (5-Year monthly) was 1.797 while the PE ratio in trailing twelve months stood at 885.71. Turning to its 52-week performance, $6.71 and $2.21 were the 52-week high and 52-week low respectively. Overall, ORGO moved 15.89% over the past month.
Organogenesis Holdings Inc’s market cap currently stands at around $629.19 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
Analysts have a consensus estimate of 90.77M for the company’s revenue for the quarter, with a low and high estimate of 87.7M and 93.8M respectively. The average forecast suggests down to a -17.47% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 488.25M, representing a 1.29% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ORGO is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend ORGO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ORGO’s current price about 15.03% and 9.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 62.80, while 7-day volatility ratio is 5.62% and 8.00% in the 30-day chart. Further, Organogenesis Holdings Inc (ORGO) has a beta value of 1.85, and an average true range (ATR) of 0.31. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -20.97% off current price level while to achieve the yearly target high, price needs to move -20.97%. Nonetheless, investors will most likely welcome a -20.97% jump to $6 which is the analysts’ median price.
If we refocus on Organogenesis Holdings Inc (NASDAQ:ORGO), historical trading data shows that trading volumes averaged 1.67 over the past 10 days and 2.13 million over the past 3 months. The company’s latest data on shares outstanding shows there are 125.73 million shares.
The 49.24% of Organogenesis Holdings Inc’s shares are in the hands of company insiders while institutional holders own 47.79% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 10.21 million on 2025-04-15, giving us a short ratio of 7.36. The data shows that as of 2025-04-15 short interest in Organogenesis Holdings Inc (ORGO) stood at 3408.9999999999995 of shares outstanding, with shares short rising to 8.62 million registered in 2025-03-14. Current price change has pushed the stock 55.00% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ORGO stock continues to rise going into the next quarter.
